<DOC>
	<DOC>NCT00097500</DOC>
	<brief_summary>This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (LantusÂ® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.</brief_summary>
	<brief_title>Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis of type 2 diabetes, but otherwise healthy HbA1c between 6.6% and 9.5%, inclusive. Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive. Treated with a stable dose of metformin for at least 2 months prior to screening. Patients previously in a study using exenatide. Treated with oral antidiabetic medications other than metformin within 2 months of screening (thiazolidinediones within 5 months of screening). Treated with insulin within 3 months of screening.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>